Table 2.
Comprehensive investigation of nuclease stability of chemically modified ONsa
| S1 nuclease |
SVPD |
50% human plasma |
|||
|---|---|---|---|---|---|
| ON | t1/2b | t1/2c | t1/2 | t1/2 | Degradation pattern |
| RNA1 | 25.4 ± 7.2 s | – | 6.0 ± 0.6 min | < 10 s | Endo |
| DNAl | 7.4 ± 1.9 s | – | 3.1 ± 0.1 min | 46.8 ± 7.0 min | Exo |
| MeRNAI | >24 h | 224 ± 47.6 min | 5.3 ± 1.5 min | 187 ± 22.6 min | Exo |
| SRNA1 | 76.8 ± 25.2 min | – | 54.4 ± 2.5 min | 65.7 ± 8.0 min | Endo |
| Me-SRNAl | >24 h | >24 h | 79.2 ± 8.7 min | 1631 ± 60.8 min | Exo |
| FRNA1 | 1.1 ± 0.1 min | – | 5.8 ± l.2 min | 53.2 ± 3.5 min | Exo |
| RNA2 | 13.0 ± 2.4 s | – | 4.3 ± 0.4 min | < 10 s | Endo |
| DNA2 | 6.6 ± 1.3 s | – | 2.7 ± 0.3 min | 31.0 ± 1.7 min | Exo |
| FRNA2 | 20.8+0.4 s | – | 6.0 ± 1.0 min | 51.9 ± 3.1 min | Exo |
| SRNA2 | 12.6 ± 1.7 min | – | 12.8 ± 3.5 min | < 10 s | Endo |
| F-SRNA2 | 6.5 ± 0.5 min | – | 21.0 ± 3.6 min | 120 ± 10.5 min | Exo |
| MeRNA2 | >24 h | 136 ± 11.5 min | 4.5 ± 1.1 min | 435 ± 12.9 min | Exo |
aErrors reflect standard deviation from three independent experiments.
bONs were treated with 0.17 U/µL S1 nuclease.
cONs were treated with 51 U/µL S1 nuclease.